Sound Pharma’s SPI-1005: A Breakthrough in Meniere's Treatment

Sound Pharmaceuticals has announced that its Phase 3 clinical trial for SPI-1005, an anti-inflammatory compound with ebselen, has achieved its co-primary efficacy endpoints for treating Meniere's disease. The study demonstrated significant improvements in hearing loss and speech discrimination, addressing a major unmet medical need as there are currently no FDA-approved treatments for this condition.

SPI-1005 was tested in a double-blind, placebo-controlled trial with 221 adult participants. Results showed superior outcomes for SPI-1005 compared to placebo in improving low-frequency hearing and speech discrimination, with continued benefits in an open-label extension.

Participants in the trial experienced significant auditory and vestibular improvements, including reduced tinnitus, vertigo, and dizziness severity. The findings support SPI-1005's potential as a transformative therapy for Meniere's disease. Further data will be presented at the Association for Research in Otolaryngology Midwinter Meeting in February 2025.